A Phase 2 Trial of Sibeprenlimab in Patients with IgA Nephropathy.
N Engl J Med. 2024.
PMID: 37916620
Free PMC article.
Clinical Trial.
Search Page
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
| Year | Number of Results |
|---|---|
| 2000 | 1 |
| 2001 | 4 |
| 2002 | 2 |
| 2003 | 1 |
| 2004 | 1 |
| 2008 | 1 |
| 2009 | 1 |
| 2010 | 1 |
| 2012 | 3 |
| 2013 | 2 |
| 2014 | 2 |
| 2015 | 7 |
| 2016 | 5 |
| 2017 | 3 |
| 2018 | 5 |
| 2019 | 2 |
| 2020 | 8 |
| 2021 | 9 |
| 2022 | 3 |
| 2023 | 7 |
| 2024 | 3 |
Search Results
63 results
Results by year
Citations
1
article
found by citation matching
Search results
Page 1
A Phase 2 Trial of Sibeprenlimab in Patients with IgA Nephropathy.
N Engl J Med. 2024 Jan 4;390(1):20-31. doi: 10.1056/NEJMoa2305635. Epub 2023 Nov 2.
N Engl J Med. 2024.
PMID: 37916620
Free PMC article.
Clinical Trial.
Lenvatinib recruits cytotoxic GZMK+CD8 T cells in hepatocellular carcinoma.
Hepatol Commun. 2023 Jul 17;7(8):e0209. doi: 10.1097/HC9.0000000000000209. eCollection 2023 Aug 1.
Hepatol Commun. 2023.
PMID: 37471053
Free PMC article.
FINDINGS: Besides its direct antitumor effects, lenvatinib recruited cytotoxic GZMK+CD8 T cells in intratumor stroma by CXCL9 from tumor-associated macrophages, suggesting that lenvatinib-treated HCC is in the so-called excluded condition that can diminish ICI efficacy....
FINDINGS: Besides its direct antitumor effects, lenvatinib recruited cytotoxic GZMK+CD8 T cells in intratumor stroma by CXCL9 from tu …
Innate immunity in allergy.
Allergy. 2019 Sep;74(9):1660-1674. doi: 10.1111/all.13788. Epub 2019 Apr 14.
Allergy. 2019.
PMID: 30891811
Free PMC article.
Review.
Functional genomics of autoimmune diseases.
Ann Rheum Dis. 2021 Jun;80(6):689-697. doi: 10.1136/annrheumdis-2019-216794. Epub 2021 Jan 6.
Ann Rheum Dis. 2021.
PMID: 33408079
Review.
Autophagy during cardiac remodeling.
J Mol Cell Cardiol. 2016 Jun;95:11-8. doi: 10.1016/j.yjmcc.2015.12.003. Epub 2015 Dec 8.
J Mol Cell Cardiol. 2016.
PMID: 26678624
Review.
Final Overall Survival Analysis From a Study Comparing First-Line Crizotinib Versus Chemotherapy in ALK-Mutation-Positive Non-Small-Cell Lung Cancer.
J Clin Oncol. 2018 Aug 1;36(22):2251-2258. doi: 10.1200/JCO.2017.77.4794. Epub 2018 May 16.
J Clin Oncol. 2018.
PMID: 29768118
Clinical Trial.
Recent advances in primary ciliary dyskinesia.
Auris Nasus Larynx. 2016 Jun;43(3):229-36. doi: 10.1016/j.anl.2015.09.012. Epub 2015 Oct 31.
Auris Nasus Larynx. 2016.
PMID: 26527516
Review.
Reevaluation of Pluripotent Cytokine TGF-β3 in Immunity.
Int J Mol Sci. 2018 Aug 1;19(8):2261. doi: 10.3390/ijms19082261.
Int J Mol Sci. 2018.
PMID: 30071700
Free PMC article.
Review.
Announcement: UEDA Heart Award for 2017.
Int Heart J. 2017;58(6):1034. doi: 10.1536/ihj.58-6_UEDA.
Int Heart J. 2017.
PMID: 29238012
Free article.
We are pleased to announce that the following 4 articles have been selected for the the UEDA Heart Awards for the Year 2017.First PlaceGeneration of Induced Pluripotent Stem Cells From Patients With Duchenne Muscular Dystrophy and Their Induction to CardiomyocytesAkihito Hashimot …
We are pleased to announce that the following 4 articles have been selected for the the UEDA Heart Awards for the Year 2017.First PlaceGener …
Novel therapeutic approaches for hepatitis B virus covalently closed circular DNA.
World J Gastroenterol. 2015 Jun 21;21(23):7084-8. doi: 10.3748/wjg.v21.i23.7084.
World J Gastroenterol. 2015.
PMID: 26109795
Free PMC article.
Review.
Although current therapies, such as the use of nucleos(t)ide analogs, inhibit HBV replication efficiently, they do not eliminate covalently closed circular DNA (cccDNA), which persists in hepatocyte nuclei. ...
Although current therapies, such as the use of nucleos(t)ide analogs, inhibit HBV replication efficiently, they do not eliminate cova …
Cite